Posts tagged “Biotech & Life Science”
RTP pharma firm expanding; CommScope revenues surge; $15M in new business for PowerSecure; LinkedIn posts loss
In today's Bulldog wrapup of life science and technology news: RTP-based Cirrus Pharmaceuticals is expanding; CommScope revenues hit $1 billion; PowerSecure books $15 million in new business; and LinkedIn reports a loss.
Research Triangle Park agricultural biotechnology startup Benson Hill Biosystems, bootstrapped with an NCBiotech loan in 2012, has been awarded nearly $100,000 by the U.S. Department of Agriculture to pursue its development of enhanced plant productivity.
Quintiles CEO Tom Pike is on the lookout for more acquisitions. In a quarterly earnings conference call Thursday, Pike said the world's largest life science services company is on the "lookout" to put acquisition targets "under our wing." Our Insider subscribers get the details.
Red Hat's new 'cloud' startup plan; Microsoft launches 'Health,' fitness band; Google 'tax;' bioMerieux 1-hour Ebola test; ChannelAdvisor adds home improvement
In today's Bulldog wrapup of tech and life science news: Red Hat aims to help startups go "cloud;" Microsoft is getting into fitness; Spain passes Google tax; a bioMerieux subsidiary offers 1-hour Ebola test; and ChannelAdvisor adds home improvement to its ecommerce suite.
INC Research, a life science services firm based in Raleigh, is looking to raise some $186 million in its IPO. That's more than $30 million higher than the initial target.. INC lost money in 2013 but is in the black so far in 2014, according to its IPO filing.
Google is working on a cancer-detecting pill in its latest effort to push the boundaries of technology. Still in the experimental stage, the pill is packed with tiny magnetic particles, which can travel through a patient's bloodstream, search for malignant cells and report their findings to a sensor on a wearable device.
Wake Emergency Physicians, PA, in partnership with TeleCommunication Systems, are launching the VirtuMedix Telehealth Platform this week at the American College of Emergency Physicians' ACEP14 in Chicago.
Drugmakers are racing to develop vaccines and drugs to address the worst outbreak of Ebola in history.
Drug giant Novartis is selling its $1-billion vaccine production plant in Holly Springs to Australia-based CSL as part of a deal valued at $275 million. Novartis is disposing its entire influenza-related vaccine business through this transaction that was announced Sunday night. Some 550 people work at the Holly Springs facility.
Some local websites run one or two tech stories per day. Others a few more but mixed with a variety of business news. At WRAL TechWire, tech and life science make up the menu with more than 50 stories published over the last five business days. Here's a look back at technology, life science and other related news as reported in WRAL TechWire last week.
WRALTechWire is continuously expanding its content lineup, and we want you to participate. We are looking for news and analysis about all things tech and life science from people who know their business.
The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March. And GSK is ramping up vaccine trial. Paul Allen chips in $100 million. But will all this be enough to stop Ebola?
Having been fined nearly $500 million in China for bribery, facing investigations in other countries and battling lagging revenue, GSK now faces more cost cuts and is contemplating a stock offering for its ViiV Healthcare. But GSK's CEO Andrew Witty defended himself and his strategy in discussing the drug giant's most recent quarterly earnings report on Wednesday. "Look at what we're able to achieve," he says.
Viamet Pharmaceuticals scrapped its plans for a $75 million IPO on Tuesday. Instead, the Triangle-based company raised $60 million in new capital. At the same time Viamet named former Glaxo CEO Bob Ingram as its chairman and spun off a new venture focused on prostate cancer.
Tens of thousands of doses of experimental Ebola vaccines -including one from GlaxoSmithKline - could be available for "real-world" testing in West Africa as soon as January as long as they are deemed safe, a top World Health Organization official said Tuesday.